Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world
2019 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world
Kapelios, C. J.; Lainscak, M.; Savarese, G.; Laroche, C.; Seferovic, P.; Ruschitzka, F. & Coats, A. et al. (2019)
European Journal of Heart Failure, 21(11) pp. 1383-1397. DOI: https://doi.org/10.1002/ejhf.1532
Documents & Media
Details
- Authors
- Kapelios, Chris J.; Lainscak, Mitja; Savarese, Gianluigi; Laroche, Cécile; Seferovic, Petar; Ruschitzka, Frank; Coats, Andrew; Anker, Stefan D. ; Crespo‐Leiro, Maria G.; Filippatos, Gerasimos; Gunes, H.
- Issue Date
- 2019
- Journal
- European Journal of Heart Failure
- ISSN
- 1388-9842
- eISSN
- 1879-0844
- Language
- English
